Horizon Kinetics Asset Management LLC Boosts Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Horizon Kinetics Asset Management LLC grew its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 10,682 shares of the company’s stock after acquiring an additional 443 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in CRISPR Therapeutics were worth $420,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Capital Market Strategies LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $461,000. KBC Group NV boosted its holdings in shares of CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock valued at $2,382,000 after buying an additional 57,696 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after buying an additional 35,196 shares in the last quarter. State Street Corp boosted its holdings in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares in the last quarter. Finally, ARK Investment Management LLC boosted its holdings in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after buying an additional 1,474,439 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 9,973 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the sale, the chief executive officer now owns 180,890 shares of the company’s stock, valued at approximately $7,673,353.80. The trade was a 5.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now directly owns 77,530 shares of the company’s stock, valued at $3,288,822.60. The trade was a 3.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Truist Financial raised their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Morgan Stanley lifted their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Royal Bank of Canada lowered their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $42.82 on Tuesday. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -9.80 and a beta of 1.77. The company has a 50 day moving average price of $43.06 and a 200-day moving average price of $45.51. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.